Community Bank N.A. Acquires 638 Shares of Pfizer Inc. (NYSE:PFE)

Community Bank N.A. raised its holdings in Pfizer Inc. (NYSE:PFE) by 0.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 156,717 shares of the biopharmaceutical company’s stock after acquiring an additional 638 shares during the period. Community Bank N.A.’s holdings in Pfizer were worth $4,512,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Briaud Financial Planning Inc bought a new position in Pfizer in the third quarter valued at about $30,000. GoalVest Advisory LLC boosted its stake in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. acquired a new stake in shares of Pfizer during the third quarter valued at about $34,000. VisionPoint Advisory Group LLC boosted its stake in shares of Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new stake in shares of Pfizer during the fourth quarter valued at about $36,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.2 %

Shares of PFE stock traded down $0.06 during trading hours on Wednesday, hitting $26.26. 24,501,011 shares of the company were exchanged, compared to its average volume of 41,887,898. The firm has a market cap of $148.70 billion, a P/E ratio of 72.94, a P/E/G ratio of 1.18 and a beta of 0.61. Pfizer Inc. has a fifty-two week low of $25.23 and a fifty-two week high of $40.37. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The company has a 50 day simple moving average of $27.05 and a two-hundred day simple moving average of $28.50.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s quarterly revenue was down 41.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.14 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.40%. Pfizer’s dividend payout ratio (DPR) is 466.67%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Guggenheim assumed coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research note on Thursday, January 4th. Eleven research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.